Three trials show ultra-low-dose checkpoint inhibitors retain efficacy with reduced toxicity and dramatically lower costs. DELII and Patil et al. trials tested low-dose nivolumab in solid tumors and HNSCC; NIVIPIT tested intratumoral low-dose ipilimumab in melanoma.
The FDA has approved a monthly dosing schedule for Rybrevant Faspro in EGFR-mutated NSCLC and granted breakthrough therapy designation for the drug as monotherapy in HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07617805 |
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC |
RECRUITING | PHASE1/PHASE2 |
